The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.

A federal appeals court overturned a judge’s approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.

A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.

A Missouri appeals court rejected Johnson & Johnson’s bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on the company’s baby powder and other talc products, but reduced its damages award to $2.12 billion from $4.69 billion.

A federal appeals court revived nationwide litigation accusing Roche Holding AG’s Genentech unit of failing to ensure that vials of the comapny’s Herceptin breast cancer drug contained the labeled amount of the active ingredient, and that the labels misstated the drug’s concentration and volume.

A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of the company’s talc-based products for feminine hygiene.

Martin Shkreli will continue to reside in federal prison after the notorious “Pharma Bro” failed to win an appeal to his 2017 criminal conviction for securities fraud and conspiracy to commit fraud.

A U.S. appeals court revived Swedish pharmaceutical company Orexo AB’s lawsuit accusing a unit of Israel’s Teva Pharmaceutical Industries Ltd. of infringing a patent for the opioid addiction drug Zubsolv.

A U.S. appeals court rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe.